Interstitial pulmonary edema induced by anlotinib
10.3760/cma.j.cn114015-20220718-00645
- VernacularTitle:安罗替尼致间质性肺水肿
- Author:
Jiaju YAN
1
;
Yuping ZHANG
Author Information
1. 六安市第二人民医院临床药学部，六安 237000
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Molecular targeted therapy;
Pulmonary edema;
Lung diseases, interstitial;
Drug-related side effects and adverse reactions;
Anlotinib
- From:
Adverse Drug Reactions Journal
2023;25(7):439-441
- CountryChina
- Language:Chinese
-
Abstract:
A 57-year-old male patient with brain metastases after radical resection of adenocarcinoma of the lung and adjuvant chemotherapy received anlotinib 12 mg orally once daily (2 weeks on and 1 week off) combined with temozolomide 150 mg orally once daily (3 weeks on and 1 week off). After 5 months of treatments, the patient developed symptoms such as cough, chest tightness, and exertional dyspnea, which gradually worsened. No obvious abnormalities were found in laboratory tests, electrocar-diogram, or cardiac echocardiography. Chest CT examination showed interstitial pulmonary edema in bilateral lungs, which was considered to be related to anlotinib. Anlotinib and temozolomide treatments were stopped and glucocorticoid and symptomatic treatments were given. Five days later, the patient′s cough, chest tightness, and other symptoms were relieved. Anlotinib was replaced by bevacizumab, which was combined with temozolomide to continue the anti-tumor treatment, and the patient did not experience discomfort. One month later, chest CT showed that the interstitial edema in bilateral lungs was markedly absorbed.
